Clinical & Research NewsFull Access
Molecular Targets Ranked
Published Online:20 Jan 2006https://doi.org/10.1176/pn.41.2.0016a
Scientists participating in the NIMH-sponsored MATRICS project ranked these molecular targets as the nine most promising targets for development of a drug to treat cognitive impairments in schizophrenia. The nine molecular targets are implicated in seven domains of cognition: working memory, attention/vigilance, verbal learning and memory, visual learning and memory, speed of processing, reasoning and problem-solving, and social cognition.
| 1. | Alpha-7 nicotinic receptor agonists | ||||
| 2. | D1 receptor agonists | ||||
| 3. | AMPA glutamatergic receptor agonists | ||||
| 4. | Alpha-2 adrenergic receptor agonists | ||||
| 5. | NMDA glutamatergic receptor agonists | ||||
| 6. | Metabotropic glutamate receptor agonists | ||||
| 7. | Glycine reuptake inhibitors | ||||
| 8. | M1 muscarinic receptor agonists | ||||
| 9. | GABA-A receptor selective agonists | ||||
